Article
Biochemistry & Molecular Biology
Seng Chuan Tang, Quentin Lion, Olivier Peulen, Philippe Chariot, Arnaud Lavergne, Alice Mayer, Paula Allepuz Fuster, Pierre Close, Sebastian Klein, Alexandra Florin, Reinhard Buettner, Ivan Nemazanyy, Kateryna Shostak, Alain Chariot
Summary: COP1 acts as an oncogenic E3 ligase by promoting ERα signaling but also acts as a tumor suppressor candidate by preventing EMT, reflecting a dual role of COP1 in breast cancer that has sparked widespread interest in the academic community.
Article
Chemistry, Medicinal
Muhammad Zafar Irshad Khan, Muhammad Uzair, Adila Nazli, Jian-Zhong Chen
Summary: Estrogen plays a crucial role in regulating various physiological actions and is particularly involved in breast cancer development. This review provides a comprehensive study on estrogen receptors and their relationship with diseases, laying a foundation for understanding the actions of estrogen and developing relevant therapeutic strategies.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Oncology
Aditi S. Khatpe, Adedeji K. Adebayo, Christopher A. Herodotou, Brijesh Kumar, Harikrishna Nakshatri
Summary: Breast cancers are broadly classified into two subtypes: estrogen receptor-positive and estrogen receptor-negative. While approximately 70% of breast cancers are estrogen receptor-positive, this type is more common in postmenopausal women. Although the majority of estrogen receptor-positive breast cancers respond to anti-estrogens, approximately 30% may recur.
Review
Oncology
Charles Dai, Leif W. Ellisen
Summary: Aberrant estrogen receptor (ER) signaling plays a key role in the development of many breast cancers. The androgen receptor (AR), similar to ER, is frequently expressed in breast cancer and has been considered as a potential therapeutic target. However, the understanding of androgen signaling in breast cancer is incomplete and there are conflicting findings regarding the role of AR. This article summarizes the current understanding of AR biology and recent investigations into AR-directed therapies in breast cancer.
Review
Biochemistry & Molecular Biology
Lea Clusan, Francois Ferriere, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer, the most common and deadliest cancer among women worldwide, is closely associated with estrogen signaling. Hormone therapy using antiestrogens is the standard treatment, but resistance inevitably occurs through various biological mechanisms. Understanding the estrogen pathway is crucial for the development of new therapies for hormone-dependent breast cancer. This mini-review summarizes the current literature on estrogen receptors in breast cancer, including their signalization, mechanisms of action, and clinical implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Paulina Miziak, Marzena Baran, Ewa Blaszczak, Alicja Przybyszewska-Podstawka, Joanna Kalafut, Jolanta Smok-Kalwat, Magdalena Dmoszynska-Graniczka, Michal Kielbus, Andrzej Stepulak
Summary: ER signaling is a critical regulator in breast cancer and other hormone-sensitive cancers. This article reviews the mechanism of ER-dependent downstream signaling in breast cancer and discusses the clinical implications of ER signaling, including potential endocrine therapies. The challenges associated with therapy resistance caused by acquired ER mutations and potential strategies to overcome them are also discussed.
Review
Biochemistry & Molecular Biology
Alexandra Moisand, Mathilde Madery, Thomas Boyer, Charlotte Domblides, Celine Blaye, Nicolas Larmonier
Summary: Breast cancers are a heterogeneous group of diseases with varying responses to current therapies. Hormone receptor-positive breast cancers can benefit from endocrine therapies, but metastatic disease remains a challenge. Immunotherapies have had limited success in breast cancer, only benefiting patients with hormone receptor-negative tumors. Current research focuses on the role of hormone receptor signaling in the sensitivity of breast cancer cells to anti-tumor immune responses and the potential of hormone therapy agents to enhance immune-based interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Lucie Malbeteau, Julien Jacquemetton, Cecile Languilaire, Laura Corbo, Muriel Le Romancer, Coralie Poulard
Summary: The progesterone receptor (PR) plays a crucial role in women's physiological and pathological responses, especially in breast cancer development. It has been found that the hormone-free form of PR is involved in maintaining the stability of breast cancer cells under hormone-depleted conditions. In this study, the researchers identified PRMT1 as a novel player in the signaling of unliganded PR.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Sea R. Choi, Chae Young Hwang, Jonghoon Lee, Kwang-Hyun Cho
Summary: In this study, a simplified but essential molecular regulatory network model was constructed through transcriptomic analysis, and inhibition of BCL11A was identified as a potential target for reprogramming basal-like cancer cells into luminal A cells.
Article
Cell Biology
Zhiguo Niu, Jianing Fan, Fengzhe Chen, Huijie Yang, Xin Li, Ting Zhuang, Chunlei Guo, Qi Cao, Jian Zhu, Hui Wang, Qingsong Huang
Summary: Breast cancer is the most common malignancy in women globally. Abnormal expression of RBCK1 protein in breast tumors makes it a valuable diagnostic marker and drug target. Hypoxic regions in breast cancer activate the HIF1 pathway, influencing tumor recurrence and metastasis. Targeting RBCK1 could be a promising treatment strategy for ER-positive breast cancer.
CELL DEATH & DISEASE
(2022)
Review
Multidisciplinary Sciences
Liliana Garcia-Martinez, Yusheng Zhang, Yuichiro Nakata, Ho Lam Chan, Lluis Morey
Summary: The majority of breast cancers express the estrogen receptor and endocrine therapy has been the mainstay for hormone-responsive breast cancer treatment. Recent studies have shown the importance of the epigenome in determining hormone therapy response and how targeting epigenetic factors can help overcome clinical resistance. Understanding epigenetic mechanisms regulating ER+ breast cancer and endocrine therapy resistance is crucial for improving targeted therapies for this type of cancer.
NATURE COMMUNICATIONS
(2021)
Review
Food Science & Technology
Livia Mateus Reguengo, Roberto de Paula do Nascimento, Ana Paula da Fonseca Machado, Mario Roberto Marostica Junior
Summary: Breast cancer has the highest incidence and mortality rates among women worldwide. Brazilian fruits and their derived products, rich in bioactive compounds, have valuable antioxidant, anti-inflammatory, and anticancer effects, and are associated with the regulation of molecular biomarkers related to breast cancer.
FOOD RESEARCH INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Erina Iwabuchi, Yasuhiro Miki, Takashi Suzuki, Hisashi Hirakawa, Takanori Ishida, Hironobu Sasano
Summary: The study investigated the biological functions of hnRNPK in the ER-mediated signaling pathway in breast cancer, finding that hnRNPK interacts with ER alpha and is involved in this pathway. Additionally, hnRNPK expression could potentially be a target for endocrine therapy in ER alpha-positive breast cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Amaia Arruabarrena-Aristorena, Eneda Toska
Summary: The majority of breast cancers are ER+, and agents targeting the ER signaling pathway have significantly improved survival for patients. However, therapeutic resistance is a challenge, particularly in metastatic cases. In recent years, disrupted epigenetic regulatory processes have been identified as major contributors to cancer development, including breast cancer. Aberrations in chromatin modifiers and transcription factors have also been associated with breast cancer development and treatment outcomes, leading to the proposal of new epigenetic-based therapies in combination with targeted treatments to overcome resistance.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Dahae Lee, Young-Mi Kim, Young-Won Chin, Ki Sung Kang
Summary: This study demonstrated that schisandrol A has estrogen-like effects by inducing the expression of ER alpha through the PI3K/AKT and ERK signaling pathways, promoting the proliferation of MCF-7 cells. The effects of schisandrol A were more significant compared to E2 and could be mitigated by the ER antagonist ICI.
Article
Multidisciplinary Sciences
Lu Wang, Hao Zeng, Qiang Wang, Zibo Zhao, Thomas G. Boyer, Xiuwu Bian, Wei Xu
Article
Biotechnology & Applied Microbiology
Hao Zeng, Li Lu, Ngai Ting Chan, Mark Horswill, Paul Ahlquist, Xuehua Zhong, Wei Xu
Meeting Abstract
Oncology
Wang Lu, Hao Zeng, Qiang Wang, Zibo Zhao, Thomas G. Boyer, Xiuwu Bian, Wei Xu
Article
Cell Biology
Fabao Liu, Fengfei Ma, Yuyuan Wang, Ling Hao, Hao Zeng, Chenxi Jia, Yidan Wang, Peng Liu, Irene M. Ong, Baobin Li, Guojun Chen, Jiaoyang Jiang, Shaoqin Gong, Lingjun Li, Wei Xu
NATURE CELL BIOLOGY
(2017)
Article
Multidisciplinary Sciences
Evgenia Shishkova, Hao Zeng, Fabao Liu, Nicholas W. Kwiecien, Alexander S. Hebert, Joshua J. Coon, Wei Xu
NATURE COMMUNICATIONS
(2017)
Article
Biochemistry & Molecular Biology
Hao Zeng, Jiacai Wu, Mark T. Bedford, Gianluca Sbardella, F. Michael Hoffmann, Kun Bi, Wei Xu
Article
Multidisciplinary Sciences
Hao Zeng, Bo Lu, Raffaella Zamponi, Zinger Yang, Kristie Wetzel, Joseph Loureiro, Sina Mohammadi, Martin Beibel, Sebastian Bergling, John Reece-Hoyes, Carsten Russ, Guglielmo Roma, Jan S. Tchorz, Paola Capodieci, Feng Cong
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2018)
Article
Biology
Hao Zeng, Johnny Castillo-Cabrera, Mika Manser, Bo Lu, Zinger Yang, Vaik Strande, Damien Begue, Raffaella Zamponi, Shumei Qiu, Frederic Sigoillot, Qiong Wang, Alicia Lindeman, John S. Reece-Hoyes, Carsten Russ, Debora Bonenfant, Xiaomo Jiang, Youzhen Wang, Feng Cong
Article
Genetics & Heredity
Hao Zeng, Wei Xu